• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

    20.56 -1.46 (-6.63%)
    Streaming Delayed Price Updated: 12:09 PM EDT, Sep 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Sarepta Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    36 37 Next >
    News headline image
    Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    Sarepta (SRPT) Q2 2026 Earnings Call Transcript ↗
    Revenue fell 34% YoY as management narrows guidance and eyes 2027 growth. 
    Via The Motley Fool
    Topics Earnings Intellectual Property
    Sarepta Therapeutics (NASDAQ:SRPT) Surges on Q2 Earnings Beat and Narrowed Outlook ↗
    Via Chartmill
    Topics Earnings
    Sarepta Therapeutics (NASDAQ:SRPT) Q1 2026 Earnings Beat Overshadowed by Revenue Dip ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Sarepta Therapeutics Q2 Earnings Call Highlights ↗
    Sarepta Therapeutics (NASDAQ:SRPT) reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
    Your hard-earned money would be better spent elsewhere. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
    Via Investor Brand Network
    NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Sarepta Therapeutics to Participate in Upcoming Investor Conferences
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
    From BioMedWire
    Via GlobeNewswire
    News headline image
    My Top 3 Biotech Stocks for May 2026 ↗
    As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd. 
    Via The Motley Fool
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta (SRPT) Q1 2026 Earnings Transcript ↗
    Sarepta (SRPT) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
    Via Investor Brand Network
    Topics Artificial Intelligence
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    Via Investor Brand Network
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug... 
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
    In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
    Via MarketMinute
    Topics Economy Intellectual Property Stocks
    News headline image
    Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
    CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular... 
    Via MarketMinute
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    36 37 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.